Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market: A Significant Driver Propelling The Ischemic Heart Disease (IHD) Drugs Market In 2025

The Ischemic Heart Disease (IHD) Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Ischemic Heart Disease (IHD) Drugs Market Size and Projected Growth Rate?
The market size for drugs treating ischemic heart disease (IHD) has experienced robust growth in recent years. It is projected to expand from $6.36 billion in 2024 to $6.71 billion in 2025, registering a compound annual growth rate (CAGR) of 5.6%. The surge in growth during the past years is primarily due to the increasing global incidence of ischemic heart disease, enhanced awareness and diagnostic procedures, alterations in lifestyle and dietary habits, government-led cardiovascular health initiatives, partnership in conducting clinical trials, and policies covering insurance and reimbursements.

In the coming years, a stable expansion is predicted for the ischemic heart disease (IHD) drugs market. It's projected to soar to $7.86 billion in 2029, with a compound annual growth rate (CAGR) of 4.0%. This predicted growth over the forecast period is due to factors such as the aging population, personalized methods in medicine, a focus on preventing cardiovascular diseases, global health policies and initiatives, as well as international research partnerships. Key trends over this forecast period encompass the shift towards precision medicine methods, concentration on developing new anti-atherogenic agents, progress in lipid-lowering treatments, the incorporation of anti-inflammatory agents, and the creation of antithrombotic and antiplatelet medications.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

What Are the Major Segments in the Ischemic Heart Disease (IHD) Drugs Market?
The ischemic heart disease (IHD) drugs market covered in this report is segmented -

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

What Are The Driving Ischemic Heart Disease (IHD) Drugs Market Evolution?
The surge of obesity and diabetes is anticipated to stimulate the ischemic heart disease (IHD) drugs market's upswing. Diabetes, a chronic metabolic illness typified by elevated blood glucose levels, and obesity, defined by an excessive buildup of body fat harmful to health, often necessitate the use of ischemic heart disease drugs in patients to manage associated cardiovascular risks such as hypertension and dyslipidemia, thereby decreasing the likelihood of ischemic heart disease. The World Obesity Federation projected in 2022 that globally by 2030, including 1 in 5 women and 1 in 7 men, one billion people will be diagnosed with obesity. Furthermore, as reported by the UK's National Health Service in June 2024, 549,000 additional individuals at risk of developing type 2 diabetes were identified by the NHS in England in 2023. As a result, the count of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP reached 3,615,330, indicating a nearly 20% increase compared to the 3,065,825 in 2022. Hence, the escalating prevalence of both obesity and diabetes fuels the expansion of the ischemic heart disease (IHD) drugs market. A spike in heart failure cases is predicted to fuel the upturn of the ischemic heart disease (IHD) drugs market. Chronic heart failure, a condition where the heart muscle cannot sufficiently pump blood to satisfy the body's need for blood and oxygen, can lead to fatigue, breathlessness, and impediments in carrying out routine activities. In treating heart failure, ischemic heart disease (IHD) drugs play a critical role. These medications serve to prevent heart failure by mitigating the risk factors and symptoms of ischemic heart disease. IHD drugs that impede the heart's pacemaker activity prove beneficial for heart failure patients who exhibit low ejection fractions and high resting heart rates despite tolerating beta-blocker. In September 2023, the Heart Failure Society of America, a U.S. entity, disclosed that 6.7 million Americans over 20 suffer from heart failure, and this figure is estimated to shoot up to 8.5 million Americans by 2030. Ergo, the rise in heart failure cases propels the growth of the ischemic heart disease (IHD) drug market.

Which Firms Dominate The Ischemic Heart Disease (IHD) Drugs Market Segments?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

What Trends Are Driving Growth in The Ischemic Heart Disease (IHD) Drugs Market?
Leading corporations in the ischemic heart disease (IHD) drugs market are devoting increased attention to the creation of progressive myosin inhibitors to establish a competitive advantage in the industry. Cardiac myosin inhibitors are medications that minimize the myosin activity in cardiac muscle, leading to reduced contraction force. These are beneficial for ailments such as hypertrophic cardiomyopathy (HCM), a condition where heart function is impaired due to over thickening of the muscles. For example, Bristol Myers Squibb, an American pharmaceutical firm, debuted Camzyos (mavacamten) in April 2022. This is the inaugural cardiac myosin inhibitor cleared for the treatment of symptomatic adults with New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy (HCM), aimed at enhancing functional capacity and symptoms. The medication functions as an allosteric and reversible inhibitor selective for cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and ameliorating cardiac filling pressures. This aids in limiting dynamic left ventricular outflow tract (LVOT) obstruction.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Which Is The Largest Region In The Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Ischemic Heart Disease (IHD) Drugs Market?
2. What is the CAGR expected in the Ischemic Heart Disease (IHD) Drugs Market?
3. What Are the Key Innovations Transforming the Ischemic Heart Disease (IHD) Drugs Industry?
4. Which Region Is Leading the Ischemic Heart Disease (IHD) Drugs Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.